TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fixed Dose Unfractionated Heparin for Initial Treatment of Venous Thromboembolism
Brief Summary: FIDO was a multicentred randomized, open-label trial that compared fixed-dose UFH with fixed-dose LMWH for initial treatment of VTE. Patients were followed for 3 months during which they received warfarin (target INR 2.0-3.0).


Options:
A: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
B: Arm Label: enoxaparin and alteplase; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin ,alteplase, unfractionated heparin | Arm Label: Unfractionated heparin and alteplase; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin ,alteplase, unfractionated heparin | Intervention Type: DRUG; Name: enoxaparin ,alteplase, unfractionated heparin; Assigned to Arm(s): Unfractionated heparin and alteplase, enoxaparin and alteplase
C: Intervention Type: DRUG; Name: UFH 250 U/kg or LMWH 100 U/kg sc twice daily; Assigned to Arm(s): N/A
D: Arm Label: innohep®; Type: EXPERIMENTAL; Interventions: Drug: innohep® | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DRUG; Name: innohep®; Assigned to Arm(s): innohep® | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: If, When and How to Ask the Question(s): Assessing Screening Approaches to Identifying Woman Abuse in Health Care Settings
Brief Summary: The purpose of the research is to evaluate whether routine screening for woman abuse in health care settings, as compared to no screening, does more good than harm. Recent reviews have identified the need for high quality research to understand 1) the actual impact on all women of instituting mass screening procedures to identify woman abuse and 2) the extent to which early identification through screening is effective in preventing or ameliorating important outcomes. The main outcomes for the study are reduction in violence, improvement in life quality, and potential harms of screening. A number of secondary outcomes to help understand the process by which screening and usual care might lead to changes in the primary outcomes will also be assessed.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Screening for intimate partner violence | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening for intimate partner violence; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Prompting (survey instrument/resources list) (behavior); Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Screening via pen and paper; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Screening via audiotape; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: If, When and How to Ask the Question(s): Assessing Screening Approaches to Identifying Woman Abuse in Health Care Settings
Brief Summary: The purpose of the research is to evaluate whether routine screening for woman abuse in health care settings, as compared to no screening, does more good than harm. Recent reviews have identified the need for high quality research to understand 1) the actual impact on all women of instituting mass screening procedures to identify woman abuse and 2) the extent to which early identification through screening is effective in preventing or ameliorating important outcomes. The main outcomes for the study are reduction in violence, improvement in life quality, and potential harms of screening. A number of secondary outcomes to help understand the process by which screening and usual care might lead to changes in the primary outcomes will also be assessed.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Screening for intimate partner violence | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening for intimate partner violence; Assigned to Arm(s): 1
B: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
C: Arm Label: TAU only; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Outpatient Treatment | Arm Label: TMAC only; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling | Arm Label: TMAC plus; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling plus incentives | Intervention Type: OTHER; Name: Intensive Outpatient Treatment; Assigned to Arm(s): TAU only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling; Assigned to Arm(s): TMAC only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling plus incentives; Assigned to Arm(s): TMAC plus
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania
Brief Summary: Trichotillomania (TTM) or hair-pulling has been considered as part of the obsessive compulsive disorder (OCD) spectrum, although treatment with OCD medications has largely been unsuccessful. Tics/Tourrettes' Syndrome (TS) is a disorder, which appears to be related to TTM, but is treated with a different class of medications than used in OCD, namely antipsychotics such as olanzapine. This is a study of the safety and efficacy of olanzapine in the treatment of hair pulling.


Options:
A: Arm Label: N-acetylcysteine (NAC); Type: EXPERIMENTAL; Interventions: Drug: N-Acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
D: Arm Label: N-Acetyl Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetyl Cysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: N-Acetyl Cysteine; Assigned to Arm(s): N-Acetyl Cysteine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Science-Based Treatment for Opioid-Dependent Adolescents
Brief Summary: The purpose of this study is to evaluate ways to optimize outcomes from combined behavioral-pharmacological treatment for opioid-dependent youth.


Options:
A: Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: behavior therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voucher-based contingency management; Assigned to Arm(s): N/A
B: Arm Label: Methadone; Type: OTHER; Interventions: Drug: Methadone | Arm Label: Buprenorphine/Naloxone; Type: OTHER; Interventions: Drug: Buprenorphine-Naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine-Naloxone; Assigned to Arm(s): Buprenorphine/Naloxone
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2
D: Arm Label: Methadone Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: Holistic Health Recovery Program; Type: EXPERIMENTAL; Interventions: Behavioral: Holistic Health Recovery Program | Arm Label: Methadone Maintenance and Holistic Health Recovery Prorgram; Type: EXPERIMENTAL; Interventions: Drug: Methadone, Behavioral: Holistic Health Recovery Program | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone Maintenance, Methadone Maintenance and Holistic Health Recovery Prorgram | Intervention Type: BEHAVIORAL; Name: Holistic Health Recovery Program; Assigned to Arm(s): Holistic Health Recovery Program, Methadone Maintenance and Holistic Health Recovery Prorgram

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Science-Based Treatment for Opioid-Dependent Adolescents
Brief Summary: The purpose of this study is to evaluate ways to optimize outcomes from combined behavioral-pharmacological treatment for opioid-dependent youth.


Options:
A: Arm Label: 1-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 2-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 4-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: buprenorphine taper followed by naltrexone maintenance; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper
B: Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: behavior therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voucher-based contingency management; Assigned to Arm(s): N/A
C: Arm Label: Buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine, Drug: Vivitrol | Arm Label: Oral naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral naltrexone, Drug: Buprenorphine, Drug: Vivitrol | Intervention Type: DRUG; Name: oral naltrexone; Assigned to Arm(s): Oral naltrexone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine, Oral naltrexone | Intervention Type: DRUG; Name: Vivitrol; Assigned to Arm(s): Buprenorphine, Oral naltrexone
D: Arm Label: Probuphine; Type: EXPERIMENTAL; Interventions: Drug: Probuphine (buprenorphine implant) | Arm Label: placebo implant; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo implant | Arm Label: sublingual buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Probuphine (buprenorphine implant); Assigned to Arm(s): Probuphine | Intervention Type: DRUG; Name: placebo implant; Assigned to Arm(s): placebo implant | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): sublingual buprenorphine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective than temozolomide in treating gliomas.

PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to temozolomide in treating patients with gliomas.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Conformal radiotherapy | Arm Label: 2; Type: OTHER; Interventions: Radiation: Conventional radiotherapy | Intervention Type: RADIATION; Name: Stereotactic Conformal radiotherapy; Assigned to Arm(s): 1 | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): 2
B: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care
C: Arm Label: radiotherapy; Type: OTHER; Interventions: Radiation: radiation therapy | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): radiotherapy
D: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Biological: CAN-2409, Drug: Valacyclovir, Drug: Temozolomide, Radiation: Radiation therapy | Intervention Type: BIOLOGICAL; Name: CAN-2409; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): Single arm | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Single arm | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Single arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
C: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial to Reduce Delirium in Aged Post Acute Patients
Brief Summary: The purpose of this study is to develop a comprehensive Delirium Abatement Program of care of delirious patients in the post acute care setting and to evaluate its impact on persistence and severity of delirium and on functional recovery.


Options:
A: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
B: Intervention Type: BEHAVIORAL; Name: Delirium Abatement Program; Assigned to Arm(s): N/A
C: Arm Label: Ketamine (0.5 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (0.5 mg/kg) | Arm Label: Normal saline (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Arm Label: Ketamine (1 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Ketamine (1 mg/kg) | Intervention Type: DRUG; Name: Ketamine (0.5 mg/kg); Assigned to Arm(s): Ketamine (0.5 mg/kg) | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal saline (placebo) | Intervention Type: DRUG; Name: Ketamine (1 mg/kg); Assigned to Arm(s): Ketamine (1 mg/kg)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: donepezil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Geriatric Resources for Assessment and Care of Elders
Brief Summary: The purpose of this study is to test the effectiveness of a collaborative model of team care as compared to usual care in improving functional outcomes among community-dwelling low-income older adults.


Options:
A: Arm Label: regular medical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: The CareWell programme; Type: EXPERIMENTAL; Interventions: Other: The CareWell programme | Intervention Type: OTHER; Name: The CareWell programme; Assigned to Arm(s): The CareWell programme
B: Arm Label: Control arm= usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: OTHER; Interventions: Other: intervention | Intervention Type: OTHER; Name: intervention; Assigned to Arm(s): Intervention arm
C: Intervention Type: BEHAVIORAL; Name: Geriatric Resources for Assessment & Care of Elders (GRACE); Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Dutch EASYcare Study Geriatric Intermediate Care Programme; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Geriatric Resources for Assessment and Care of Elders
Brief Summary: The purpose of this study is to test the effectiveness of a collaborative model of team care as compared to usual care in improving functional outcomes among community-dwelling low-income older adults.


Options:
A: Arm Label: Control arm= usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: OTHER; Interventions: Other: intervention | Intervention Type: OTHER; Name: intervention; Assigned to Arm(s): Intervention arm
B: Intervention Type: BEHAVIORAL; Name: Geriatric Resources for Assessment & Care of Elders (GRACE); Assigned to Arm(s): N/A
C: Arm Label: Patient Group 1; Type: EXPERIMENTAL; Interventions: Other: Health TAPESTRY Intervention | Arm Label: Patient Group 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Health TAPESTRY Intervention; Assigned to Arm(s): Patient Group 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Patient Group 2
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Mobile Geriatric Team intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Geriatric Team intervention; Assigned to Arm(s): Intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Energy Restriction and Metabolic Aging in Humans
Brief Summary: The purpose of this study is to develop an effective calorie restricted diet.


Options:
A: Arm Label: Intermittent Energy Restriction; Type: EXPERIMENTAL; Interventions: Behavioral: Intermittent Energy Restriction | Arm Label: Continuous Energy Restriction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Continuous Energy Restriction | Intervention Type: BEHAVIORAL; Name: Intermittent Energy Restriction; Assigned to Arm(s): Intermittent Energy Restriction | Intervention Type: BEHAVIORAL; Name: Continuous Energy Restriction; Assigned to Arm(s): Continuous Energy Restriction
B: Intervention Type: BEHAVIORAL; Name: Dietary composition and energy intake; Assigned to Arm(s): N/A
C: Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Arm Label: Mediterranean diet; Type: EXPERIMENTAL; Interventions: Other: Mediterranean diet | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): Mediterranean diet | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Time-Restricted Feeding (early in the day eating); Type: EXPERIMENTAL; Interventions: Other: Time-Restricted Feeding | Arm Label: Grazing; Type: PLACEBO_COMPARATOR; Interventions: Other: Grazing | Intervention Type: OTHER; Name: Time-Restricted Feeding; Assigned to Arm(s): Time-Restricted Feeding (early in the day eating) | Intervention Type: OTHER; Name: Grazing; Assigned to Arm(s): Grazing

Answer: B